Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.39 +3.4%	$1.34	$0.86 ▼ $3.78	$300.76M	0.31	3.32 million shs	1.05 million shs
AUPH Aurinia Pharmaceuticals	$8.25 +0.8%	$7.99	$5.20 ▼ $10.67	$1.11B	1.15	1.33 million shs	310,031 shs
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
GPCR Structure Therapeutics	$21.06 -2.9%	$22.64	$13.22 ▼ $49.91	$1.20B	-1.87	850,642 shs	156,993 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	-5.63%	+20.72%	-27.57%	-42.98%
AUPH Aurinia Pharmaceuticals	0.00%	-0.12%	-0.12%	-2.62%	+44.78%
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	+3.17%
GPCR Structure Therapeutics	0.00%	+2.60%	-13.87%	-0.50%	-54.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	3.8686 of 5 stars	4.5	3.0	0.0	0.0	3.0	3.3	0.6
AUPH Aurinia Pharmaceuticals	3.2734 of 5 stars	3.5	2.0	0.0	0.0	4.1	0.8	1.9
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	2.265 of 5 stars	3.5	2.0	0.0	0.0	2.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.90	Moderate Buy	$8.44	509.71% Upside
AUPH Aurinia Pharmaceuticals	3.00	Buy	$11.50	39.48% Upside
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
GPCR Structure Therapeutics	3.00	Buy	$76.50	263.25% Upside

Current Analyst Ratings Breakdown

Latest ALLO, CALT, GPCR, and AUPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	ALLO Allogene Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
5/14/2025	ALLO Allogene Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $7.00
5/14/2025	ALLO Allogene Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$12.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/12/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $75.00
5/2/2025	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
4/22/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
3/19/2025	ALLO Allogene Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $8.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$22K	13,770.11	N/A	N/A	$3.04 per share	0.46
AUPH Aurinia Pharmaceuticals	$247.30M	4.50	N/A	N/A	$2.63 per share	3.13
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$9.77 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$327.27M	-$1.23	N/A	N/A	N/A	N/A	-52.13%	-41.29%	8/6/2025 (Estimated)
AUPH Aurinia Pharmaceuticals	-$78.02M	$0.28	N/A	14.72	N/A	-10.23%	-4.41%	-3.07%	7/30/2025 (Estimated)
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
GPCR Structure Therapeutics	-$89.62M	-$0.87	N/A	N/A	N/A	N/A	-16.37%	-15.68%	8/6/2025 (Estimated)

Latest ALLO, CALT, GPCR, and AUPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A
5/12/2025	Q1 2025	AUPH Aurinia Pharmaceuticals	$0.08	$0.16	+$0.08	$0.16	$61.06 million	$62.47 million
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.35	9.35
AUPH Aurinia Pharmaceuticals	0.17	5.60	5.11
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
GPCR Structure Therapeutics	N/A	27.63	27.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
AUPH Aurinia Pharmaceuticals	36.83%
CALT Calliditas Therapeutics AB (publ)	2.83%
GPCR Structure Therapeutics	91.78%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
AUPH Aurinia Pharmaceuticals	12.20%
CALT Calliditas Therapeutics AB (publ)	2.20%
GPCR Structure Therapeutics	9.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.73 million	158.72 million	Optionable
AUPH Aurinia Pharmaceuticals	300	135.10 million	137.02 million	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.86 million	Optionable

ALLO, CALT, GPCR, and AUPH Headlines

Recent News About These Companies

Handelsbanken Fonder AB Buys 215,000 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

June 13 at 4:23 AM | marketbeat.com

Brokers Offer Predictions for GPCR FY2026 Earnings

June 13 at 3:01 AM | americanbankingnews.com

Structure Therapeutics (NASDAQ:GPCR) Trading Down 4.5% - Time to Sell?

June 12, 2025 | marketbeat.com

Cantor Fitzgerald Estimates GPCR FY2025 Earnings

June 12, 2025 | americanbankingnews.com

Structure Therapeutics (NASDAQ:GPCR) Shares Up 9.4% - Still a Buy?

June 11, 2025 | marketbeat.com

Equities Analysts Set Expectations for GPCR FY2026 Earnings

June 11, 2025 | marketbeat.com

Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $76.50 Average Target Price from Analysts

June 11, 2025 | americanbankingnews.com

Cantor Fitzgerald Predicts GPCR FY2025 Earnings

June 10, 2025 | marketbeat.com

Structure Therapeutics: Why Aleniglipron's Path To Market Remains Treacherous

June 10, 2025 | seekingalpha.com

Structure Therapeutics Inc. (NASDAQ:GPCR) Given Average Recommendation of "Buy" by Brokerages

June 8, 2025 | marketbeat.com

Bank of America Corp DE Has $1.47 Million Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

June 5, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Makes New $3.09 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)

June 3, 2025 | marketbeat.com

BNP Paribas Financial Markets Makes New $304,000 Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)

May 29, 2025 | marketbeat.com

Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 4.6% - Here's Why

May 28, 2025 | marketbeat.com

Zimmer Partners LP Sells 154,200 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

May 23, 2025 | marketbeat.com

Vestal Point Capital LP Raises Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)

May 21, 2025 | marketbeat.com

Wexford Capital LP Sells 16,351 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

May 21, 2025 | marketbeat.com

Tema Etfs LLC Acquires New Shares in Structure Therapeutics Inc. (NASDAQ:GPCR)

May 20, 2025 | marketbeat.com

Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Sold by Point72 Europe London LLP

May 18, 2025 | marketbeat.com

Structure Therapeutics Inc. (NASDAQ:GPCR) Receives Average Recommendation of "Buy" from Analysts

May 16, 2025 | marketbeat.com

Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights

May 9, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
By Leo Miller | June 14, 2025
View Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY
By Thomas Hughes | June 11, 2025
View Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY

ALLO, CALT, GPCR, and AUPH Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.38 +0.05 (+3.36%)

As of 12:24 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Aurinia Pharmaceuticals NASDAQ:AUPH

$8.24 +0.07 (+0.79%)

As of 12:24 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 06/13/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Structure Therapeutics NASDAQ:GPCR

$21.06 -0.62 (-2.86%)

As of 12:24 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time